Biologic therapy in severe asthma: An update
Open Access
- 28 August 2019
- journal article
- Published by Heighten Science Publications Corporation in Archives of Asthma, Allergy and Immunology
- Vol. 3 (1), 003-009
- https://doi.org/10.29328/journal.aaai.1001016
Abstract
No abstract availableThis publication has 43 references indexed in Scilit:
- Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trialsThe Lancet Respiratory Medicine, 2015
- Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic AsthmaThe New England Journal of Medicine, 2014
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaThe New England Journal of Medicine, 2014
- The eXpeRience registry: The ‘real-world’ effectiveness of omalizumab in allergic asthmaRespiratory Medicine, 2013
- Dupilumab in Persistent Asthma with Elevated Eosinophil LevelsThe New England Journal of Medicine, 2013
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialThe Lancet, 2012
- Reslizumab for Poorly Controlled, Eosinophilic AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard TherapyAnnals of Internal Medicine, 2011
- The mechanisms, diagnosis, and management of severe asthma in adultsThe Lancet, 2006
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004